Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

ng the compound have a lower rate of relapse," said Dr. Elizabeth Mittendorf, senior author on the study and Principal Investigator for the trial.  "These studies help us to understand at a mechanistic level how the vaccine is working and on a more general level what hallmarks to look for in developing successful cancer immunotherapy."

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery o
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... (PRWEB) November 23, 2014 Apiscent ... supplier of fine chemical ingredients to the global ... launch of its new website, Apiscent.com. , The ... Apiscent Labs, clean design, easy navigation, rotating images ... Apiscent Labs stand out. , The ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
(Date:11/22/2014)... November 21, 2014   ... Chief Commercial Officer zu KLOX    ... und Chief Financial Officer bestellt    ... Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen ... das "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... MA - In work that could jumpstart the promising field ... body to treat a variety of diseases and tissue defects, ... that could solve one of the key challenges associated with ... transplantation. In the work, reported in the journal ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... has published results from the North American Phase 3 trial ... fidaxomicin as a treatment for patients with Clostridium difficile ... significantly reduced recurrence rates and increased global cure rates when ...
... ST. LOUIS, Feb. 2, 2011 Sigma Life Science, the ... SIAL ), today announced that its SAGE Labs initiative ... genomes for six of the most widely used strains of ... generate and analyze sequence data using next generation sequencing systems, ...
Cached Biology Technology:Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 2The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 4The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 5The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 6Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 3Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 4
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... A tiny, fast switch that uses water droplets to create ... mechanism found in palm beetles. , The new beetle-inspired ... on the scale of a micron -- a millionth of ... larger applications like powerful adhesive bonding. Like the transistor, whose ...
... that the brains of alcoholics are smaller, lighter ... speakers at the October 2004 Congress for the ... Mannheim, Germany reviewed what is known about the ... shrinkage. Proceedings are published in the June issue ...
... and Infectious Diseases (NIAID), part of the National Institutes ... which cause such serious diseases as West Nile fever, ... defenses in different ways depending on whether they are ... to new approaches to developing vaccines and treatments against ...
Cached Biology News:Beetle-inspired switch uses water for bonding 2Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: